Clinical Trial Update: Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 trial evaluating the dosing schedule and timing of trametinib in children with BRAF-negative histiocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Histiocytosis

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: Anna Raciborska | Conditions: Histiocytosis | Phase 2 | Status: RECRUITING